Evidence map›Paper›PMID 41862512›Full record

ArticleScientific reports2026

Macrophages recruited by implanted fibrin gels promote regeneration of injured lymphatic vessels.

Mohammad S Razavi, Pin-Ji Lei, Zohreh Amoozgar, Meghan J O'Melia, Kangsan Roh, Nichaluk Leartprapun, Seemantini K Nadkarni, James W Baish, Timothy P Padera, Lance L Munn

Abstract read
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Mohammad S RazaviEdwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital Cancer Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA, 02114, USA.
Pin-Ji LeiEdwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital Cancer Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA, 02114, USA.
Zohreh AmoozgarEdwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital Cancer Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA, 02114, USA.
Meghan J O'MeliaEdwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital Cancer Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA, 02114, USA.
Kangsan RohEdwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital Cancer Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA, 02114, USA.
Nichaluk LeartprapunWellman Center for Photomedicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02114, USA.
Seemantini K NadkarniWellman Center for Photomedicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02114, USA.
James W BaishBiomedical Engineering, Bucknell University, Lewisburg, PA, 17837, USA.
Timothy P PaderaEdwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital Cancer Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA, 02114, USA. tpadera@mgh.harvard.edu.
Lance L MunnEdwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital Cancer Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA, 02114, USA. lmunn@mgh.harvard.edu.

Funding

Systems biology of lymphatic transportR01HL128168 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI MUNN, LANCE L., PADERA, TIMOTHY P · 2015 to 2019
$2.9M
Targeting lymph node metastases to block cancer progressionR01CA284372 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI TIMOTHY P PADERA · 2023 to 2026
$2.0M
Systems Biology of Antigen and T-Cell Transport in Cancer ImmunotherapyR01CA284603 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI Lance L. Munn, TIMOTHY P PADERA · 2023 to 2026
$1.9M
Vascularized tumor explants for drug testingR01CA247441 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI MUNN, LANCE L. · 2021 to 2025
$1.9M
Multiplexed device for rapid coagulopathy testingR21EB031982 · NIBIB · MASSACHUSETTS GENERAL HOSPITAL · PI HARDIN, CHARLES COREY, MUNN, LANCE L. · 2021 to 2021
$462k
Reversing aging-induced lymphatic dysfunction to improve immune functionR21AG072205 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI PADERA, TIMOTHY P · 2022 to 2023
$458k
Regeneration and remodeling of collecting lymphatic vessels post-injuryF32HL156654 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI RAZAVI RIZI, MOHAMMAD · 2021 to 2024
$212k
NCI NIH HHS R01 CA247441NCI NIH HHS R01 CA284372NCI NIH HHS R01 CA284603NHLBI NIH HHS F32 HL156654NHLBI NIH HHS R01 HL128168NIA NIH HHS R21 AG072205NIBIB NIH HHS R21 EB031982NIH HHS F32HL156654NIH HHS R01CA284603NIH HHS R01HL128168
6 · The paper itself

Abstract

Secondary lymphedema is a debilitating condition driven by impaired regeneration of lymphatic vasculature following lymphatic injury, surgical removal of lymph nodes in cancer patients, or infection. However, the extent to which collecting lymphatic vessels regenerate following injury remains unclear. Here, we employed a novel mouse model of lymphatic injury in combination with state-of-the-art lymphatic imaging to demonstrate that the implantation of an optimized fibrin gel following lymphatic vessel injury leads to the reconnection of the injured lymphatic vessel network through sprouting lymphangiogenesis of initial-like lymphatic vessels from the ends of the collecting lymphatic vessels, resulting in the restoration of lymph flow to the draining lymph node. Mechanistically, we found that fibrin implantation elevates the tissue levels of CCL5, a potent immune cell-recruiting chemokine. Notably, injured vessels in CCL5-KO mice made fewer connections following fibrin gel implantation. These novel findings shed light on the mechanisms underlying lymphatic regeneration and suggest that enhancing CCL5 signaling may be a promising therapeutic strategy for enhancing lymphatic regeneration.

Indexed as

FibrinLymphatic VesselsLymphedemaMacrophagesRegenerationAnimalsChemokine CCL5Disease Models, AnimalGelsLymphangiogenesisMiceMice, Inbred C57BLMice, KnockoutCcl5 protein, mouseChemokine CCL5FibrinGelsCollecting lymphatic vesselsLymphatic injuryLymphatic pumpingLymphatic regenerationLymphedema

Identifiers

PMID41862512
PMCPMC13144344

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.